Published on June 28 2023

Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis

Pile de livres colorés hardback un livre ouvert sur fond bleu

New publication in Jama Network Open

The PEPITES team has just published an article in JAMA Network Open on the risk of severe COVID-19 associated with multiple sclerosis (MS) and anti-CD20 antibody treatments as part of Edouard Januel's epidemiology thesis (supervised by Caroline Papeix and Florence Tubach).

The risk of severe COVID-19 was higher in patients with progressive MS compared to those with relapsing-remitting MS. An increased risk of severe COVID-19 associated with anti-CD20 treatments was observed in patients with relapsing-remitting MS.

More information